Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 42 Gy Radiation Therapy Clear all
Completed Phase 2 Interventional Results available

Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"

NCT03621696
View directory record Official record
Conditions
HPV Related Oropharyngeal Squamous Cell Carcinoma
Interventions
Cisplatin, Intensity modulated radiation therapy, Intensity modulated proton therapy, Surgery, FACT-H&N, MD Anderson Dysphagia Inventory, University of Michigan Xerostomia Index, Scale of Subjective Total Taste Acuity, Neck Dissection Impairment Index
Drug · Radiation · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer

NCT00468169
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, 5-FU, Hydroxyurea, Twice-daily radiation, Cisplatin, Accelerated fraction radiotherapy with concomitant boost
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 15, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT05327686
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
323
States / cities
Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 248 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 15, 2026, 1:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

NCT04421378
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Drug · Radiation · Device
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 15, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

NCT06816927
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
Nivolumab, Relatlimab, TMZ, Radiation Therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 15, 2026, 1:32 PM EDT
Recruiting Not applicable Interventional

Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer

NCT07643012
View directory record Official record
Conditions
Endometrial Cancer
Interventions
MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT02186847
View directory record Official record
Conditions
Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions
Radiation Therapy, Carboplatin, Metformin, Paclitaxel
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
219
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Auburn, California + 176 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00274833
View directory record Official record
Conditions
CNS Tumor, Adult
Interventions
erlotinib hydrochloride, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
David Peereboom
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer

NCT00423293
View directory record Official record
Conditions
Anal Cancer
Interventions
fluorouracil, mitomycin C, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
169
States / cities
Tucson, Arizona • Auburn, California • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer

NCT00858663
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
intensity modulated radiation therapy, RAD001 (everolimus) + Cisplatin
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers

NCT05120947
View directory record Official record
Conditions
Resectable Head and Neck Squamous Cell Carcinoma
Interventions
42 Gy Radiation Therapy, 39 Gy Radiation Therapy, 32.5 Gy Radiation Therapy
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 15, 2026, 1:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer

NCT06529809
View directory record Official record
Conditions
Locally Advanced Cervical Carcinoma
Interventions
Hypofractionated external beam radiation, Chemotherapy, Image-guided brachytherapy
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer

NCT01215500
View directory record Official record
Conditions
Tumor, Cancer, Melanoma, Sarcoma, Carcinoma
Interventions
Hypofractionated RT
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 15, 2026, 1:32 PM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
Interventions
Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer

NCT00047008
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, Standard fractionation RT, Accelerated fractionation radiation therapy, Conventional surgery for select patients
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
195
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 15, 2026, 1:32 PM EDT
Not listed Phase 3 Interventional Results available

A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

NCT00667888
View directory record Official record
Conditions
Prostate Cancer
Interventions
Conventional Fractionated Intensity Modulated Radiotherapy, Hypofractionated Intensity Modulated Radiotherapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation

NCT01402063
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
PPX (CT2103), Temozolomide
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
La Jolla, California • Scarborough, Maine • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma

NCT03137888
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Dose-Escalated Radiation Therapy, Spectroscopic Magnetic Resonance Imaging, Temozolomide
Radiation · Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT01062399
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
concurrent RAD001 10 mg/day, concurrent temozolomide, Radiation therapy, concurrent RAD001 2.5 mg/day, concurrent RAD001 5 mg/day, post-radiation RAD001 10 mg/day, post-radiation temozolomide
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
34
States / cities
Newark, Delaware • Gainesville, Florida • Jacksonville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 15, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

NCT04988074
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma
Interventions
Cemiplimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

NCT03232424
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
NovoTTF-200A, Temozolomide, 3D conformal or intensity modulated radiation therapy (IMRT)
Device · Drug · Radiation
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 15, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

NCT00766636
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Radiation Therapy, Erlotinib, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 15, 2026, 1:32 PM EDT
Active, not recruiting Phase 1 Interventional

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

NCT03587038
View directory record Official record
Conditions
Glioblastoma
Interventions
OKN 007, Temozolomide, Photon/Proton IMRT
Drug · Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 15, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

NCT05038332
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ultra-hypofractionated radiation therapy, Moderately Hypo-fractionated Radiation Therapy
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 15, 2026, 1:32 PM EDT